Abstract
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two mostcommon neurodegenerative disorders encountered in clinical practice. Whilstdementia has long been synonymous with AD, it is becoming more widely acceptedas part of the clinical spectrum in PD (PDD). Neuropsychiatric complications,including psychosis, mood and anxiety disorders, and sleep disorders also frequentlyco-exist with cognitive dysfunctions in AD and PDD patients. The incidence of suchsymptoms is often a significant source of disability, and may aggravate pre-existingcognitive deficits. Management of AD and PDD involves both pharmacological and non-pharmacologicalmeasures. Although research on pharmacological therapies for AD and PDD has so far had some success in terms ofdeveloping symptomatic treatments, the benefits are often marginal and non-sustained. These shortcomings have led tothe investigation of non-pharmacological and novel treatments for both AD and PD. Furthermore, in light of the diverseconstellation of other neuropsychiatric, physical, and behavioural symptoms that often occur in AD and PD, considerationneeds to be given to the potential side effects of pharmacological treatments where improving one symptom may lead tothe worsening of another, rendering the clinical management of these patients challenging. Therefore, the present articlewill critically review the evidence for both pharmacological and non-pharmacological treatments for cognitive impairmentin AD and PD patients. Treatment options for other concomitant neuropsychiatric and behavioural symptoms, as well asnovel treatment strategies will also be discussed.
Keywords:Alzheimer’s disease, cognition, dementia, mild cognitive impairment, non-pharmacological treatment, Parkinson’sdisease, pharmacological treatment.
Graphical Abstract
Current Neuropharmacology
Title:Current Treatment Options for Alzheimer’s Disease and Parkinson’s Disease Dementia
Volume: 14Issue: 4
Author(s):Jennifer Y.Y. Szeto and Simon J.G. Lewis
Affiliation:
Keywords:Alzheimer’s disease, cognition, dementia, mild cognitive impairment, non-pharmacological treatment, Parkinson’sdisease, pharmacological treatment.
Abstract: Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two mostcommon neurodegenerative disorders encountered in clinical practice. Whilstdementia has long been synonymous with AD, it is becoming more widely acceptedas part of the clinical spectrum in PD (PDD). Neuropsychiatric complications,including psychosis, mood and anxiety disorders, and sleep disorders also frequentlyco-exist with cognitive dysfunctions in AD and PDD patients. The incidence of suchsymptoms is often a significant source of disability, and may aggravate pre-existingcognitive deficits. Management of AD and PDD involves both pharmacological and non-pharmacologicalmeasures. Although research on pharmacological therapies for AD and PDD has so far had some success in terms ofdeveloping symptomatic treatments, the benefits are often marginal and non-sustained. These shortcomings have led tothe investigation of non-pharmacological and novel treatments for both AD and PD. Furthermore, in light of the diverseconstellation of other neuropsychiatric, physical, and behavioural symptoms that often occur in AD and PD, considerationneeds to be given to the potential side effects of pharmacological treatments where improving one symptom may lead tothe worsening of another, rendering the clinical management of these patients challenging. Therefore, the present articlewill critically review the evidence for both pharmacological and non-pharmacological treatments for cognitive impairmentin AD and PD patients. Treatment options for other concomitant neuropsychiatric and behavioural symptoms, as well asnovel treatment strategies will also be discussed.
Export Options
About this article
Cite this article as:
Szeto Y.Y. Jennifer and Lewis J.G. Simon, Current Treatment Options for Alzheimer’s Disease and Parkinson’s Disease Dementia, Current Neuropharmacology 2016; 14 (4) .https://dx.doi.org/10.2174/1570159X14666151208112754
| DOI https://dx.doi.org/10.2174/1570159X14666151208112754 | Print ISSN 1570-159X |
| Publisher Name Bentham Science Publisher | Online ISSN 1875-6190 |
Call for Papers in Thematic Issues
Advances in Neuroinflammation and Neuroprotection: Mechanisms and Therapeutic Frontiers
It offers a comprehensive exploration of neuroinflammatory and neuroprotective pathways that play central roles in a range of neurological disorders, including stroke, traumatic brain injury, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This issue invites research on the cellular and molecular mechanisms driving neuroinflammation, such as the roles of ...read more
Advances in paediatric and adult brain cancers: emerging targets and treatments
Brain tumors are the most common solid tumors affecting children and adolescents, with up to 5,000 children diagnosed per year. Pediatric brain tumors, because of their location, are often untreatable and their clinical management can cause significant long-term impairment to intellectual and neurological function with epilepsy and neurodegeneration. Other than ...read more
Cannabis in Health and Disease
Cannabis-based products span a history of over 4,000 years, with their regular purposes in numerous religious rituals, traditional systems of medicine, cosmetics, and hedonic activities. The discovery and cloning of cannabinoid receptors in mammalian tissues provided direct evidence of the physiological significance of targeting these receptors with endogenously synthesized and ...read more
Emotion (Dys)regulation: An integration of Pharmacological, Neurobiological, and Psychological Frameworks
Emotion regulation is a critical aspect of mental well-being and interpersonal relationships. To fully understand and effectively address emotion regulation, an integrative approach that considers pharmacological, neurobiological, and psychological frameworks is essential. Pharmacological interventions, such as medications targeting neurotransmitter imbalances, can play a significant role in managing emotional dysregulation. Understanding ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
Andrographolide and its Analogs: Botanical Sources, Phytochemistry, Pharmacology, and Biotechnology
Frontiers in Clinical Drug Research-Dementia
Anthocyanins: Pharmacology and Nutraceutical Importance
The Roles and Responsibilities of Clinical Pharmacists in Hospital Settings
Interventional Pain Surgery
Endoscopy and Fetoscopy Techniques for the Brain and Neuroaxis
Bioactive Compounds from Medicinal Plants for Cancer Therapy and Chemoprevention
Regenerative Medicine & Peripheral Nerve Endoscopy
Advances in Diagnostics and Immunotherapeutics for Neurodegenerative Diseases
Drug Addiction Mechanisms in the Brain
83
8
1
1
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
- N-alkylated Tacrine Derivatives as Potential Agents in Alzheimer’s Disease Therapy
Current Alzheimer ResearchMicroalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals?
Current Pharmaceutical DesignRheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued)Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies
Current Alzheimer ResearchTransplantation of Stem Cells as a Potential Therapeutic Strategy in Neurodegenerative Disorders
Current Stem Cell Research & Therapy Preclinical Analyses of the Therapeutic Potential of Allopregnanolone to Promote Neurogenesis In Vitro and In Vivo in Transgenic Mouse Model of Alzheimers Disease
Current Alzheimer Research Telomere/Telomerase System: A New Target of Statins Pleiotropic Effect?
Current Vascular PharmacologyShould Percutaneous Coronary Intervention be the Standard Treatment Strategy for Significant Coronary Artery Disease in all Octogenarians?
Current Cardiology ReviewsXenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design
Current Topics in Medicinal Chemistry Detection of Amyloid-β Aggregates in Body Fluids: A Suitable Method for Early Diagnosis of Alzheimers Disease?
Current Alzheimer Research Cannabinoid System in Neurodegeneration: New Perspectives in Alzheimers Disease
Mini-Reviews in Medicinal ChemistryThe Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction
Current Pharmaceutical Design Melatonin-mitochondria Interplay in Health and Disease
Current Topics in Medicinal ChemistryHumans Entrain to Sunlight - Impact of Social Jet Lag on Disease and Implications for Critical Illness
Current Pharmaceutical DesignTargeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical DesignLocation Tracking Mechanisms for Dementia Patients
Recent Patents on EngineeringModulatory Effect of Sinapic Acid in Toluene Induced Dementia of Leukoencephalopathy Type in Wistar Rats: a Biochemical Study
The Natural Products JournalAmygdalar Atrophy in Early Alzheimer’s Disease
Current Alzheimer ResearchInsights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Cognitive Impairment in the Septic Brain
Current Neurovascular Research